We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study of MK-3009 in Japanese Patients With Skin or Blood Stream Infections Caused by Methicillin-resistant Staphylococcus Aureus (MK-3009-002)

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00770341
First Posted: October 10, 2008
Last Update Posted: October 12, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Merck Sharp & Dohme Corp.
  Purpose
The study investigates the efficacy and safety of MK-3009 in participants with skin infections, septicemia and right-sided infective endocarditis (RIE) caused by methicillin-resistant Staphylococcus aureus (MRSA).

Condition Intervention Phase
Staphylococcal Infection Drug: Daptomycin 4 mg/kg Drug: Comparator: vancomycin Drug: Daptomycin 6 mg/kg Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase III Randomized, Open-labeled Clinical Trial of MK-3009 (Daptomycin) in Patients With Skin and Soft Tissue Infections, Septicemia and Right-sided Infective Endocarditis Caused by MRSA

Resource links provided by NLM:


Further study details as provided by Merck Sharp & Dohme Corp.:

Primary Outcome Measures:
  • Efficacy Adjudication Committee (EAC) Assessment of Number of Participants With Clinical Success at Test of Cure (TOC) [ Time Frame: 7-14 days for SSTI, 14-42 days for septicemia and right-sided infective endocarditis (RIE) ]

    Clinical Success = Study investigator's Clinical Response confirmed by the EAC as either cured or improved at end of treatment (EOT).

    MITT-MRSA (modified intent-to-treat - methicillin-resistant Staphylococcus aureus) was a subset of allocated participants with participants who were excluded for any of the following reasons: no MRSA isolated + any 1 of the following: failure to receive ≥1 dose of study drug, lack of all post-allocation primary and secondary endpoint data after ≥1 dose of study drug, no gram (+) coccus isolated at baseline.


  • Efficacy Adjudication Committee (EAC) Assessment of Number of Participants With Microbiological Response at TOC [ Time Frame: 7-14 days for SSTI, 14-42 days for septicemia and RIE ]

    Response = eradicated or presumed eradicated.

    Eradicated was defined as absence of the admission pathogen in a culture obtained in the absence of potentially effective antibiotics for the pathogen.

    Presumed eradicated was defined as no material for culture was available due to improvement of infection, but the admission pathogen was presumed to be eradicated because the participant was deemed "Cured" or "Improved" by the investigator and the participant did not receive potentially effective antibiotics for the pathogen.



Secondary Outcome Measures:
  • EAC Assessment of Number of Participants With Clinical Success at End of Treatment (EOT). [ Time Frame: 7-14 days for SSTI, 14-42 days for septicemia and RIE ]
    Clinical Success = Study investigator's Clinical Response confirmed by the EAC as either cured or improved at EOT.

  • EAC Assessment of Number of Participants With Microbiological Response at End of Treatment (EOT). [ Time Frame: 7-14 days for SSTI, 14-42 days for septicemia and RIE ]

    Response = eradicated or presumed eradicated.

    Eradicated was defined as absence of the admission pathogen in a culture obtained in the absence of potentially effective antibiotics for the pathogen.

    Presumed eradicated was defined as no material for culture was available due to improvement of infection, but the admission pathogen was presumed to be eradicated because the participant was deemed "Cured" or "Improved" by the investigator and the participant did not receive potentially effective antibiotics for the pathogen.


  • Study Investigators' Assessment of Clinical Response at EOT [ Time Frame: 7-14 days for SSTI, 14-42 days for septicemia and RIE ]
    Clinical Success = Study investigator's Clinical Response confirmed by the EAC as either cured or improved at EOT.

  • Study Investigators' Assessment of Clinical Response at TOC [ Time Frame: 7-14 days for SSTI, 14-42 days for septicemia and RIE ]
    Clinical Success = Study investigator's Clinical Response confirmed by the EAC as either cured or improved at EOT.


Enrollment: 122
Study Start Date: September 2008
Study Completion Date: February 2010
Primary Completion Date: February 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: MK-3009 (daptomycin) 4 mg/kg Drug: Daptomycin 4 mg/kg
MK3009 (daptomycin) once daily by intravenous (IV) drip, 4 mg/kg for 7-14 days for skin and soft tissue infections (SSTI)
Other Name: MK3009
Active Comparator: Vancomycin Drug: Comparator: vancomycin
vancomycin 1g, twice daily (b.i.d.) by IV drip, for 7-14 days
Experimental: MK-3009 (daptomycin) 6 mg/kg Drug: Daptomycin 6 mg/kg
MK-3009 (daptomycin) once daily by intravenous drip, 6 mg/kg for 14-42 days for septicemia or right-sided infective endocarditis

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   20 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Both Sexes, Aged 20 Years Or Older
  • Japanese Participants With Skin And Soft Tissue Infections, Septicemia, or RIE Known Or Suspected To Be Caused By MRSA
  • Written Informed Consent

Exclusion Criteria:

  • Participants With Skin and Soft Tissue infections That Can Be Treated By Surgery Alone
  • Participants With Pneumonia
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00770341


Sponsors and Collaborators
Merck Sharp & Dohme Corp.
Investigators
Study Director: Medical Monitor Merck Sharp & Dohme Corp.
  More Information

Publications:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Merck Sharp & Dohme Corp.
ClinicalTrials.gov Identifier: NCT00770341     History of Changes
Other Study ID Numbers: 3009-002
2008_564
First Submitted: October 9, 2008
First Posted: October 10, 2008
Results First Submitted: May 17, 2011
Results First Posted: June 15, 2011
Last Update Posted: October 12, 2017
Last Verified: February 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description:

http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf

http://engagezone.msd.com/ds_documentation.php


Additional relevant MeSH terms:
Infection
Communicable Diseases
Staphylococcal Infections
Gram-Positive Bacterial Infections
Bacterial Infections
Vancomycin
Daptomycin
Anti-Bacterial Agents
Anti-Infective Agents